ALKS 7290 Phase 1b topline in ADHD
Alkermes reported results from its Phase 1b study of ALKS 7290 for ADHD in Q3 2026 (Jul–Sep). The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Alkermes plc ALKS
- Drug
- ALKS 7290
- For
- ADHD
- Stage
- Phase 1b
- When
- Q3 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Q2 2026 earnings call (Jul 28, 2026): top-line results expected by the end of the third quarter of 2026.
- Checked
- Checked by a person when it was added
- Source: finance.yahoo.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ALKS headlines on this site
Alkermes expects to report results from its Phase 3 study of Alixorexton (ALKS 2680) for Idiopathic hypersomnia in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Vibrance-3 Phase 2 completion in idiopathic hypersomnia · Clinical trial results (readout / topline data)
- Drug
- Alixorexton (ALKS 2680)
- For
- Idiopathic hypersomnia
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings call: Vibrance-3 study completion expected in Q4 2026, with topline data to follow; split-dose arm still enrolling.
- Checked
- Checked by a person when it was added
- Verify it
- Source: finance.yahoo.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ALKS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
sNDA submission for LUMRYZ in idiopathic hypersomnia by year-end 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Alkermes (LUMRYZ (sodium oxybate ER) for idiopathic hypersomnia): a step in the program rather than a decision or a data readout.
More details
- Entry
- sNDA submission for LUMRYZ in idiopathic hypersomnia by year-end 2026 · Company milestone
- Drug
- LUMRYZ (sodium oxybate ER)
- For
- idiopathic hypersomnia
- Stage
- sNDA
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- REVITALYZ Phase 3 topline PR (May 12, 2026), reiterated on Q2 2026 call. Note: contractual restriction bars marketing LUMRYZ for IH before March 1, 2028, regardless of approval timing.
- Checked
- Checked by a person when it was added
- Verify it
- Source: stocktitan.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ALKS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Alkermes expects to report results from its Phase 3 study of Alixorexton (ALKS 2680) for Narcolepsy type 1 and type 2 during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Brilliance Phase 3 studies completion in narcolepsy (NT1/NT2) · Clinical trial results (readout / topline data)
- Drug
- Alixorexton (ALKS 2680)
- For
- Narcolepsy type 1 and type 2
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 earnings call: Phase 3 Brilliance studies (initiated April 2026) completion expected in 2027 (year-level precision only); alixorexton holds FDA Breakthrough Therapy designation in NT1.
- Checked
- Checked by a person when it was added
- Verify it
- Source: finance.yahoo.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ALKS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page